GAGulnara Abdilova

Gulnara Abdilova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gulnara Abdilova has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. SYSTEMATIC REVIEW

    by G.T. Tashenova, G.K. Abdilova, D.N. Kairbaeva, A. Sarmoldina, R.F. Sabitova, G.E. Omarova, M.R. Rabandiyarov

    Introduction.Minimal residual disease (MRD) is a key predictor of relapse and survival in pediatric acute lymphoblastic leukemia (ALL), as well as a central component of risk-adapted treatment protocols, including the BFM approach. [1,2] Aim. To present data from a systematic review on MRD monitoring in pediatric ALL and to compare the advantages and prognostic value of the main MRD detection methods (multicolor/next-generation flow cytometry, Ig/TCR-RQ-PCR, and NGS), as well as factors influencing the reliability of results. Search strategy. A systematic search was conducted in PubMed and Scopus databases and peer-reviewed journals covering publications from 2010 to 2025. Studies on pediatric ALL describing MRD detection methods, time points of assessment, and treatment outcomes (EFS/OS/relapse), as well as current guidelines defining MRD standards, were included. Results. MRD levels reflect the effectiveness of treatment protocols and clinical management strategies, including treatment intensification in patients with disease progression and consideration of alternative therapeutic approaches in cases of persistent MRD. [15,16] Within the BFM protocol, the most significant MRD is observe d on day 15 and at the end of induction therapy (day 33), with a broad threshold of 10⁻⁴(0.01%). [3,4] Multicolor flow cytometry (MFC/NGF) enables rapid decision-making, while molecular methods (Ig/TCR-RQ-PCR, NGS) improve analytical sensitivity and reproducibility, maintaining standard quality parameters (LOD/LOQ, QA, hemodilution control). [1,5,6] MRD dynamics between days 15 and 33 provide independent prognostic information. [3,7] Conclusions. MRD monitoring in pediatric acute lymphoblastic leukemia is an essential component of risk-adapted therapy. For clinical application, standardized bone marrow sampling, defined limits of detection and quantification, and consistent interpretation of MRD levels and their dynamics according to protocol are required. [1,5,6] Введение. Минимальная остаточная болезнь (МОБ) - это основной предиктор рецидива и выживаемости при остром лимфобластном лейкозе (ОЛЛ) у детей, а также ключевой элемент риск-адаптированных протоколов, включая подход BFM. [1,2] Цель. Представить данные систематического обзора о мониторинге МОБ при ОЛЛ у детей и сравнить преимущества и прогностическую ценность основных методов обнаружения МОБ (многоцветная/проточная цитометрия следующего поколения, Ig/TCR-RQ-PCR, NGS) и факторы, определяющие надежность результатов. Стратегия поиска. Был проведен систематический поиск в базах данных PubMed, Scopus, журналов по публикациям за с 2010 по 2025 год. Включены исследования по детскому ОЛЛ, описывающие методы определения МОБ, временные точки и результаты лечения (EFS/OS/рецидив), а также текущие руководства приводящие к стандарту МОБ. Результаты. Показатели МОБ отражают эффективность протоколов и тактики ведения: интенсификация лечения у пациентов с прогрессированием и обсуждение альтернативных методов лечения при персистирующей МОБ [15,16]. В BFM-подходе наиболее значительная МОБ наблюдается на 15-й день и в конце индукции (33-й день) с пороговым значением широкого спектра 10⁻⁴ (0,01%). [3,4] Многоцветная проточная цитометрия (MCF/NGF) обеспечивает высокую нагрузку и скорость принятия решения; молекулярные методы (Ig/TCR-RQ-PCR, NGS) повышают аналитическую чувствительность и воспроизводимость при сохранении стандартных показателей качества (LOD/LOQ, QA, контроль гемодилюции). [1,5,6] Динамика разрешения МОБ в период с 15 по 33 день предоставляет независимую прогностическую информацию. [3.7] Выводы: Мониторинг МОБ у детей с острым лимфобластным лейкозом является важным компонентом терапии, адаптированной к риску. Для клинического применения необходимы стандартизированный забор костного мозга, определение пределов обнаружения и количественного определения, интерпретация уровней МОБ и их динамики в соответствии с протоколом. [1,5,6] Кіріспе. Минималды қалдық ауру (МОА) — балалардағы жедел лимфобластты лейкоз (ЖЛЛ) кезінде рецидив пен өмір сүру ұзақтығының негізгі болжамдық көрсеткіші, сондай-ақ BFM тәсілін қоса алғанда, қауіпке бейімделген хаттамалардың маңызды элементі болып табылады. [1,2] Мақсаты. Балалардағы ЖЛЛ...

  • Retinoblastoma in Kazakhstan: Incidence Trends and Survival Analysis (2015–2024)

    by Alua Aubakirova, Akmaral Abikulova, Lyazat Manzhuova, Nazgul Akhtayeva, Aigulsum Izekenova, Gulnara Abdilova, Dinara Berlibek, Farida Sarsekbayeva, Zhanerke Serikova, Neilya Aldasheva

    Introduction: Retinoblastoma (Rb) is a rare but aggressive pediatric eye cancer. This study aimed to examine its epidemiological characteristics, diagnostic stages, and survival factors in Kazakhstan, where national-level data have previously been limited. Methods: A retrospective national registry study was conducted using data from the Scientific Center for Pediatrics and Pediatric Surgery, the country’s referral center for Rb (2015–2024). Incidence was calculated using a birth cohort approach per 100,000 live births. Demographic and clinical characteristics, including diagnostic intervals (lag time 1: symptom onset to diagnosis; lag time 2: diagnosis to treatment initiation), were analyzed. Survival was estimated using Kaplan-Meier methods. Prognostic factors were assessed using univariate and multivariable Cox proportional hazards regression. Results: A total of 167 cases were recorded. The cumulative birth cohort incidence was 4.18 per 100,000 live births (1:23,915). Median age at diagnosis was 14 months (IQR: 6.5–27.5). Unilateral disease occurred in 78.4% of patients, and 76.9% were diagnosed at advanced stages (D or E). Extraocular involvement was observed in 9.8% of affected eyes. Hereditary Rb accounted for 6% of cases. Median lag time 1 was 60 days (IQR: 30–120), and median lag time 2 was 12 days (IQR: 7–20). Overall mortality was 11.4%, with most deaths occurring within 18 months. Older age at diagnosis (adjusted HR: 1.031; 95% CI: 1.008–1.054; p = 0.009) and longer lag time 2 (adjusted HR: 1.006; 95% CI: 1.004–1.008; p < 0.001) were independently associated with increased mortality. Conclusion: Rb in Kazakhstan remains characterized by a high proportion of advanced-stage disease and measurable early mortality. Delays in treatment initiation and older age at diagnosis independently predict poorer survival, underscoring the need to strengthen early detection and optimize care pathways.

  • Open Access

    Pharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy

    by Zaure Dushimova, Timur Saliev, Aigul Bazarbayeva, Gaukhar Nurzhanova, Ainura Baibadilova, Gulnara Abdilova, Ildar Fakhradiyev

    Over the past decades, remarkable progress in multimodal therapy has significantly improved survival outcomes for children with cancer. Yet, considerable variability in treatment response and toxicity persists, often driven by underlying genetic differences that affect the pharmacokinetics and pharmacodynamics of anticancer drugs. Pharmacogenomics, the study of genetic determinants of drug response, offers a powerful approach to personalize pediatric cancer therapy by optimizing efficacy while minimizing adverse effects. This review synthesizes current evidence on key pharmacogenetic variants influencing the response to major classes of antineoplastic agents used in children, including thiopurines, methotrexate, anthracyclines, alkylating agents, vinca alkaloids, and platinum compounds. Established gene–drug associations such as TPMT, NUDT15, DPYD, SLC28A3, and RARG are discussed alongside emerging biomarkers identified through genome-wide and multi-omics studies. The review also examines the major challenges that impede clinical implementation, including infrastructural limitations, cost constraints, population-specific variability, and ethical considerations. Furthermore, it highlights how integrative multi-omics, systems pharmacology, and artificial intelligence may accelerate the translation of pharmacogenomic data into clinical decision-making. The integration of pharmacogenomic testing into pediatric oncology protocols has the potential to transform cancer care by improving drug safety, enhancing treatment precision, and paving the way toward ethically grounded, personalized therapy for children.


  • Open Access

    The Use of Paediatric Early Warning Signs to Detect Clinical Deterioration in Children with Oncohematological Diseases

    by Yedil Kurakbayev, Kuanysh Umbetov, Yergali Sarsekbayev, Botagoz Turdaliyeva, Lyazat Manzhuova, Abay Kussainov, Gulnara Abdilova

    Aim: The aim is to highlight the importance of early detection, the efficacy of pediatric early warning signs (PEWS), and their implications for clinical practice, focusing on the specific signs that affect the detection and management of clinical deterioration in children with oncological diseases.Methods: The review included English-language studies retrieved from common databases using the keywords “pediatric,” “Early Warning Signs,” “clinical deterioration,” combined with terms related to “onchohematological” and “pediatric cancers.”Results: Sixteen articles were analyzed. The analysis revealed that the PEWS cohort was associated with a lower incidence of unplanned codes (p = 0.0001), cardiopulmonary arrest (P = 0.0001), and mortality (P = 0.01). The incidence of critical deterioration between the cohorts showed no significant variation (P = 0.07).Conclusion: PEWS significantly contributes to reducing mortality rates, unplanned codes, and cardiopulmonary arrest. However, further research is required to address the limitations and challenges associated with its application in this population


  • INTERNATIONAL EXPERIENCE IN APPLYING THE SYSTEM OF PEDIATRIC EARLY WARNING SIGNS OF CRITICAL CONDITIONS IN ONCOLOGICAL CHILDREN: A LITERATURE REVIEW

    by Ye. Kurakbayev, B. Turdaliyeva, L. Manzhuova, K. Omarova, G. Abdilova, A. Kusainov, S. Saparbayev, V. Schukin

    Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.


  • INTERNATIONAL EXPERIENCE IN APPLYING THE SYSTEM OF PEDIATRIC EARLY WARNING SIGNS OF CRITICAL CONDITIONS IN ONCOLOGICAL CHILDREN: A LITERATURE REVIEW

    by Ye. Kurakbayev, B. Turdaliyeva, L. Manzhuova, K. Omarova, G. Abdilova, A. Kusainov, S. Saparbayev, V. Schukin

    Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.


  • ҚАЗАҚСТАН РЕСПУБЛИКАСЫНДАҒЫ БАЛАЛАР МЕН ЖАСӨСПІРІМДЕРДЕ SARS-COV-2-КЕ БАЙЛАНЫСТЫ ДАМЫҒАН КӨПЖҮЙЕЛІ ҚАБЫНУ СИНДРОМЫ

    by И.с. Джаксыбаева, Р.з. Боранбаева, С.т. Абдрахманова, Р.с. Майтбасова, П.к. Ишуова, Д.а. Баешева, Н.а. Малтабарова, А.к. Катарбаев, К.а. Умешева, Т.в. Маршалкина, et al.

    Мультисистемный воспалительный синдром (МВС), ассоциированный с COVID-19, представляет собой тяжелое гипервоспалительное состояние у детей и подростков, связанное с предшествующей инфекцией SARS-CoV-2, характеризующееся лихорадкой, воспалением и мультисистемным поражением. Было проведено ретроспективное исследование у детей с МВС, ассоциированным с SARS-CoV-2, получавших стационарное лечение в многопрофильных детских медицинских организациях 17 регионов Казахстана c 1 августа 2020г. по 15 июня 2022г. Всего в исследование вошло 96 пациентов. У большинства пациентов наблюдались изменения в общем анализе крови, повышение маркеров воспаления. Половина детей нуждались в лечении отделение реанимации и интенсивной терапии (ОРИТ). Целью данного исследования является описание клинических проявлений и наиболее частых изменений в лабораторных показателях у детей с МВС, ассоциированным с SARS-CoV-2 в РК. COVID-19-мен ассоциирленген көп жүйелі қабыну синдромы (КҚС) – балалар мен жасөспірімдердегі SARS-CoV-2 инфекциясымен байланысты, қызбамен, қабынумен және көпжүйелі зақымданумен сипатталатын ауыр гиперқабыну жағдайы. 2020 жылдың 1- тамызынан бастап 2022 жылдың 15-маусымына дейін Қазақстанның 17 облысында көп бейінді балалар медициналық ұйымдарында стационарлық ем қабылдаған SARS-CoV-2-мен байланысты КҚС бар балаларға ретроспективті зерттеу жүргізілді. Зерттеуге барлығы 96 науқас қатысты. Пациенттердің көпшілігінде жалпы қан анализінде өзгерістер, қабыну маркерлерінің жоғарылауы байқалды. Балалардың жартысы жансақтау бөлімінде емделуді қажет етті. Multisystem inflammatory syndrome (MIS-С) associated with COVID-19 is a severe hyperinflammatory condition in children and adolescents associated with a previous SARS-CoV-2 infection, characterized by fever, inflammation and multisystem lesion. A retrospective study was conducted in children with MIS associated with SARS-CoV-2 who received inpatient treatment in multidisciplinary children's medical organizations in 17 regions of Kazakhstan from August 1, 2020 to June 15, 2022. A total of 96 patients were included in the study. The majority of patients had changes in the general blood test, increased markers of inflammation. Half of the children needed treatment in the intensive care unit (ICU). The purpose of this study is to describe the clinical manifestations and the most frequent changes in laboratory data in children with MVS associated with SARS-CoV-2 in the Republic of Kazakhstan.

  • Open Access

    Acute myeloid leukemia mmicking an Ewing’s sarcoma family tumor: A clinical case

    by S. Baiturova, K. Omarova, R. Boranbaeva, G. Abdilova, O. Pankova, A. Bekisheva, A. Makhneva, G. Batyrkhanova, T. Kustova

    ОНКОЛОГИЯ и РАДИОЛОГИЯ КАЗАХСТАНА

  • Open Access

    A clinical case of acute myeloid leukemia mimicking a tumor of the Ewing sarcoma family

    by S. M. Baiturova, K. O. Omarova, R. Z. Boranbaeva, G. K. Abdilova, O. S. Pankova, A. N. Bekisheva, A. F. Makhneva, G. Z. Batyrkhanova, T. A. Kustova

    ОНКОЛОГИЯ и РАДИОЛОГИЯ КАЗАХСТАНА